Value of 2016 FDA drug approvals: reversion to the mean?

被引：4

作者：

Schulze, Ulrik ^{[1
]}

Ringel, Michael ^{[2
]}

Panier, Valery ^{[2
]}

Baedeker, Mathias ^{[3
]}

机构：

[1] Boston Consulting Grp Inc, Munstergasse 2, CH-8001 Zurich, Switzerland

[2] Boston Consulting Grp Inc, Exchange Pl,31st Floor, Boston, MA 02109 USA

[3] Boston Consulting Grp Inc, Ludwigstr 21, D-80539 Munich, Germany

来源：

关键词：

D O I：

10.1038/nrd.2017.8

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：78 / 78

页数：1

共 50 条

[1] Value of 2016 FDA drug approvals: reversion to the mean?
Ulrik Schulze
Michael Ringel
Valery Panier
Mathias Baedeker
[J]. Nature Reviews Drug Discovery, 2017, 16 : 78 - 78
[2] 2016 FDA drug approvals
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (02) : 73 - 76
[3] 2016 FDA drug approvals
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2017, 16 : 73 - 76
[4] 2015 FDA drug approvals
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2016, 15 : 73 - 76
[5] 2013 FDA drug approvals
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2014, 13 : 85 - 89
[6] 2014 FDA drug approvals
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2015, 14 : 77 - 81
[7] Recent FDA drug approvals
Naccari, Christopher
[J]. CNS SPECTRUMS, 2008, 13 (06) : 466 - 466
[8] 2008 FDA drug approvals
Hughes, Bethan
[J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (02) : 93 - 96
[9] 2011 FDA drug approvals
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2012, 11 (2) : 91 - 94
[10] 2012 FDA drug approvals
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2013, 12 : 87 - 90